BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37280407)

  • 1. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
    Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
    BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
    Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
    Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
    Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
    Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
    Franzese C; Badalamenti M; Comito T; Franceschini D; Clerici E; Navarria P; Loi M; D'agostino G; Baldaccini D; Chiola I; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Radiother Oncol; 2020 Sep; 150():184-190. PubMed ID: 32593644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
    Tan H; Cheung P; Louie AV; Myrehaug S; Niglas M; Atenafu EG; Chu W; Chung HT; Poon I; Sahgal A; Soliman H
    Radiother Oncol; 2021 Aug; 161():159-165. PubMed ID: 34119585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases.
    Sole CV; Lopez Guerra JL; Matute R; Jaen J; Puebla F; Rivin E; Sanchez-Reyes A; Beltran C; Bourgier C; Calvo FA; Marsiglia H
    Clin Transl Oncol; 2013 Jun; 15(6):484-91. PubMed ID: 23143953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of split-course stereotactic ablative radiotherapy for oligometastases.
    Paik EK; Kim MS; Seo YS; Jang WI; Kang JK; Cho CK; Yoo HJ
    Jpn J Clin Oncol; 2018 Jun; 48(6):548-554. PubMed ID: 29722825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
    J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.